home > epc > autumn 2003 > electronic tools for drug development and registration from a cro's perspective
European Pharmaceutical Contractor

Electronic Tools for Drug Development and Registration from a CRO's Perspective

A medium-sized CRO needs to balance their resources carefully in a rapidly changing legal environment. It is vital to have the tools available to serve the needs of both international and national clients and to fine-tune the range of services.

For the core areas of clinical operations, regulatory affairs and data management, different tools are currently available either as software on a license basis or as a service provided by specialised suppliers.

The actual scope, taking the German scenario into account, is:

e-Trials (electronic data capture, e-trial tracking and e-trial management)
Electronic 'AWB' (drug surveillance)
Electronic common technical document (electronic tools for the eCTD)


Electronic data capture has been discussed in numerous articles and meetings for a considerable period of time. The advantages are numerous, the most important, among others, being:

Rapidly available clinical data drives a trial forward with fast decision-making processes
To change the role of the CRA
To avoid the bottleneck for data management in the data cleaning and query resolution prior to database lock
To encourage investigators to complete the electronic case report form quickly and to ease the process of reporting

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

By Dr Uwe Albrecht, Managing Director of Mediconomics GmbH and Chief Executive Officer of Mediconomics Inc

Dr Uwe W Albrecht started his professional life in 1984 at Behringwerke, Marburg/Lahn where he worked as a CRA on Phase II and Phase III trials in oncology and haematology. By the end of 1987, Dr Albrecht joined Glaxo GmbH, Germany, from which he moved on to Glaxo Group Research Ltd, London, as Senior Clinical Research Scientist in 1990. Moving back to Germany, Dr Albrecht joined Wellcome Germany, mainly focussing on drug development in virology.

In 1993, he was employed at the Institut für Gesundheitsforschung (Institute for Health Research) near Munich as Director of Clinical Research and Regulatory Affairs. From 1995 to 1997, Dr Albrecht worked as Scientific Director with Norgine, Marburg, before joining Pharmakopius International as Head of German Operations. In 1999, he joined Mediconomics GmbH, Hannover as Managing Director.

Dr Uwe Albrecht
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo maintains its dual-terminal operations seamlessly

Completing the gradual transition process to Istanbul Airport, one of the largest airports of the world, the global air cargo brand Turkish Cargo maintains its dual-terminal operations with full capacity on 7/24 basis without any sales restriction.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach


Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

Industry Events



SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement